TP53 and Miyoshi myopathy: Importantly, genetic analyses from the CoMMpass study have identified a particularly aggressive subset of newly diagnosed MM patients (6.1%) termed double-hit myeloma, defined by bi-allelic inactivation of the TP53 tumor suppressor gene in combination with 1q amplification—alterations detectable only via next-generation sequencing [114].